We analyzed three single-nucleotide polymorphisms (SNPs) at the interleukin-10 (IL-10) 5 0 flanking region (positions À1082 A/ G, À819 C/T and À592 C/A) in an association case-control study involving 248 patients with plaque type of psoriasis and 148 unrelated healthy volunteers using ARMS (amplification refractory mutation system)-PCR (Polymerase Chain Reaction) method. No difference was found in the frequencies of haplotype distribution between healthy controls and patients with psoriasis. There were no significant differences in the IL-10 haplotype distribution depending on the age of onset and family history of psoriasis. However, the results of our study demonstrate that the IL-10 haplotype has a role in determining severity and course of plaque type of psoriasis. IL-10 ACC haplotype (Po0.05) is likely to be defining lower activity of disease (PASIr20; extentr10%) and ATA haplotype is likely to be associated with persistent eruption (Po0.01). As ACC haplotype is suggested to be associated with high IL-10 secretion and ATA is related to low IL-10 secretion, potential differences in the IL-10 secretion levels might contribute the differences in the clinical course of psoriasis.
Psoriasis is a common cutaneous disorder characterized by inflammation and abnormal epidermal proliferation with a prevalence of 2-3% in the general population. Psoriasis is considered to be a T-cell-mediated autoimmune disease in which a relative interleukin-10 (IL-10) deficiency seems to have crucial importance. 1 Results from twin and family studies have suggested that B75% of the variation in IL-10 production is genetically determined. 2 The gene-encoding IL-10 maps on the long arm of chromosome 1 in the q31-q32 region and its 5 0 flanking region contains numerous polymorphisms. 3 Three single-nucleotide polymorphisms (SNPs) at promoter region (À1082 or À1087 G/A, dbSNP 1800896; À819 or À824 C/T, dbSNP 3021097 and À592 or À597 C/A, dbSNP 1800872) are in complete linkage disequilibrium, 4 and generally three haplotypes exist in Caucasian populations (GCC, ACC, ATA). 5 The GTA haplotype is extremely rare in Caucasians, but it has reported in a study by Eskdale et al. 6 The polymorphisms at promoter region of the IL-10 gene are in close proximity to several transcription factors that may interfere with gene transcription. 7 It was demonstrated in vitro and in vivo that a genetic variation in the IL-10 gene promoter region at these positions is related to the production of IL-10. [8] [9] [10] The previous report suggested that the GCC haplotypes have been associated with higher and the ATA with lower IL-10 production. 10 Contrarily Eskdale et al found that the A allele at position À1082 was associated with higher IL-10 secretion than the G allele, comparing the haplotypes R2-(IL10.G13)-A-C-C and R2-(IL10.G13)-G-C-C. 6 Previous studies have presented evidence for an association between IL-10 SNPs with susceptibility, severity and prognosis for a number of autoimmune, malignant and infectious diseases. [11] [12] [13] Up to now only few studies have showed an association between IL-10 promoter SNPs and the susceptibility to psoriasis. 14, 15 In the light of the above findings, the aim of this study was to determine the distribution of the IL-10 5 0 flanking region haplotypes in psoriasis patients and in healthy controls, and to investigate whether polymorphisms at IL-10 promoter region influence susceptibility to and/or severity in this chronic skin disease.
All the subjects enrolled in this study, patients and control subjects, were Caucasian living in Estonia. They all gave written informed consent for the study, as indicated in the approval note by the Ethics Review Committee on Human Research of the University of Tartu. A total of 248 (n ¼ 248) patients with plaque-type psoriasis, unrelated to one another, were examined in the Department of Dermatology and Venerology, University of Tartu. None of the patients suffered from other dermatoses. Patients with psoriasis were considered to have early onset disease if disease onset was before 40 years (n ¼ 177) and late onset psoriasis if age of onset was X40 years (n ¼ 71). Age at onset was defined as the time at which the patient first became aware of psoriatic skin lesions. In addition, patients were considered to have familial psoriasis if they have at least one first-or second-degree relative with psoriasis (n ¼ 99), or to have sporadic psoriasis (n ¼ 149), if they have no affected relatives. We excluded the patients treated with systemic psoriasis therapy at the time of the examination from the further analysis. Disease severity was quantified by the Psoriasis Area and Severity Index (PASI). 16 The PASI scores were calculated on the basis of the degree of erythema, desquamation and infiltration of lesions, combined with surface extension. A total, 229 patients (n ¼ 229) were examined and the patients were divided into two groups according to the PASI scores (PASI p20 and PASI 420). The higher PASI score represents a greater degree of psoriatic severity. Disease severity was also scored solely in terms of the extent of the skin lesions at the time of the examination and the patients were divided into three groups: p10%; 11-30% and 430% of psoriatic involvement of the body. The course of psoriasis was qualified as intermittent, if recurrently eruption get well, and persistent, if rash remains static or progress. The control group consisted of 148 unrelated healthy volunteers free from the positive family history of psoriasis. Individuals with a history of other dermatoses were not included in the control group. Characteristics of the study participants are shown in Table 1 .
To detect the nucleotides at positions À592, À819 and À1082, we applied ARMS (amplification refractory mutation system)-PCR (Polymerase Chain reation). Described method has been widely used for screening of multiple SNPs and recently description for IL-10 SNPs has been published. 12 Haplotype frequencies of IL-10 SNPs were calculated and compared between the psoriatic patients and the controls, using standard w 2 analysis. Haplotype frequencies were also compared within patient subgroups and the controls according to age of onset and family history of psoriasis, severity and course of the disease. P-values were calculated for each variable. Significance was defined as a probability value less than 0.05.
We found that 44.9% of the control population had the haplotype GCC, 26.4% had ACC and 28.0% had ATA. One healthy volunteer had the haplotype GTA. The frequencies of haplotypes in Estonian were similar to those noted in previously published report in Caucasians. 8 The GTA haplotype is extremely rare in Caucasians, but it has also been reported previously in a study by Eskdale et al. 6 Haplotype frequencies for IL-10 promoter SNPs were compared between psoriasis patients and controls, and results are presented in Table 2 . There were no significant differences in the haplotype distribution of IL-10 SNPs depending on the age of onset and family history of psoriasis.
The distribution of haplotypes according to the severity, extent and the course of disease are shown in Table 3 . The distribution of haplotypes in patients with higher PASI score (PASI 420) and in controls did not differ (P ¼ 0.79). More patients with lower PASI score (PASI p20) had the ACC haplotype than controls (Po0.05). Likewise more patients with limited eruption (extent p10%) had the ACC haplotype than healthy controls (Po0.05). In addition to comparing the distribution of IL-10 haplotypes between patients with intermittent and persistent eruption, we found that more patients with persistent eruption had the haplotype ATA (Po0.01).
As psoriasis seems to be induced by the relative deficit of IL-10, our hypothesis was that IL-10 haplotypes should define disease susceptibility and/or severity of psoriasis. When we analyzed the frequencies of haplotypes in patients with intermittent and persistent course of disease, a clear haplotype skewing was established. Patients with persistent eruption have more likely ATA haplotype. Therefore, it is possible that they produce IL-10 at lower levels than patients with intermittent course. Our results also show a significant increase of ACC haplotype among patients with milder form of psoriasis (extent r10%, PASI r20). It appears that ACC haplotype should be protective in the assessment of disease severity. This finding fits well with several recent papers where the positive results between different IL-10 haplotypes and the course of autoimmune disease have found. 10, 11 The relation between different haplotypes (GCC or ACC) and the IL-10 production level is not clear yet. In earlier studies, GCC haplotype has been suggested to be associated with higher IL-10 production, but recent paper describes the relation of ACC with higher IL-10 production. 6, 10 If ACC haplotype is really associated with higher IL-10 production level than GCC or ATA, it is very tempting to speculate that genetically determined IL-10 production level might contribute to the differences in the clinical course and severity of plaque type of psoriasis found in our study. However, further studies are needed to clarify that contradiction.
In summary, we conclude that IL-10 gene would be first of all disease-modifying gene than susceptibility gene in psoriasis and its promoter polymorphisms influence the clinical course of disease.
